ImmunoCellular (OTC: IMUC.OB) Notches Deal For New Cancer Stem Cell Vaccine Target
December 2nd, 2009
In an option agreement announced today with MD Anderson Medical Center, ImmunoCellular Therapeutics (OTC: IMUC.OB) has acquired the rights to novel peptides that elicit a T-cell immune response against validated cancer stem cell targets known as the Notch and Numb pathways.